Completed PHASE2 INTERVENTIONAL NCT00272558

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma

Sponsor: Rigshospitalet, Denmark

Conditions Malignant Pleural Mesothelioma

Interventions Carboplatin and Vinorelbine

Updated 5 times since 2017 Last updated: Sep 17, 2009 Started: Sep 30, 2004 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00272558, this PHASE2 trial focuses on Malignant Pleural Mesothelioma and remains completed. Sponsored by Rigshospitalet, Denmark, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rigshospitalet, Denmark

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark